MIAMI, March 5, 2025 /PRNewswire/ -- Immorta Bio Inc., a leader in longevity-focused biotechnologies, announced today acceptance of its poster presentation at the upcoming Society for Immunotherapy of ...

MIAMI BEACH, Fla., July 26, 2024 /PRNewswire/ -- Immorta Bio Inc, a science-based longevity company dedicated to treating "Diseases of Aging and Aging as a Disease™" with personalized cellular ...

MIAMI BEACH, Fla., Nov. 25, 2025 /PRNewswire/ -- Immorta Bio Inc., a scientific longevity company pioneering therapies focusing on Treating Diseases of Aging and Treating Aging as Disease™, today ...

Immorta Bio's innovative platform SenoVax™, a dendritic cell-based vaccine designed to target and eliminate senescent cells. Preclinical studies have demonstrated its potential to transform the tumor ...

MIAMI, May 5, 2025 /PRNewswire/ -- Immorta Bio Inc, a scientific longevity company dedicated to "Treating Diseases of Aging and Treating Aging as Disease", announced it is presenting a talk called ...

Scientific Longevity Company Collaborates with Major Academic Institutions to Remove Tumor Defense Mechanisms and Help Defeat Cancer in a Non-Toxic Manner MIAMI, Dec. 4, 2025 /PRNewswire/ -- Immorta ...

Breakthrough Study Highlights SenoVax™'s Potential to Transform Cancer Treatment MIAMI, Dec. 18, 2024 /PRNewswire/ -- Immorta Bio Inc., a leader in longevity-focused biotechnologies, has announced the ...

Immorta Bio Inc, a science-based life extension company developing efficient and practical personalized stem cell platforms aimed at treating diseases of aging and treating aging as disease, has ...

Immorta Bio's innovative platform SenoVax(TM), a dendritic cell-based vaccine designed to target and eliminate senescent cells. Preclinical studies have demonstrated its potential to transform the ...